Investors

Human Utility Value

“We are building a community of shareholder partners with a vision to optimize Human Utility Value while maximizing shareholder return. BioHarvest Sciences offers investors a rare opportunity to participate in a disruptive technology that promises both sustainable corporate growth AND improves human Health & Wellness.”

— Ilan Sobel, CEO

***May 2 Corporate Update Webinar Recording Now Available***

CEO Ilan Sobel and Chairman Zaki Rakib hosted an interactive Corporate Update to discuss recent milestones, including the acquisition of a new corporate campus and the Full Year 2023 financials, which included a 130% revenue increase over 2022. This live event also featured an Investor Question + Answer session.

Watch May 2 Webinar Recording

BioHarvest Sciences is a global leader in Botanical Synthesis and Plant Cell Biology

  • Innovative and disruptive Botanical Synthesis Platform opening the gate for patentable Botanical Drugs
    • New Contract Development and Manufacturing business unit launched February 26, 2024 with two industry contracts.  Pharma, Cosmeceutical, Nutraceutical and Nutrition customers can now develop patentable and consistent  plant-based molecules using our process.
  • Our patented Botanical Synthesis technology has been validated by the successful commercialization of VINIA, the first product developed on our platform.
    • FY 2023 Revenue Increased 2.3x to $12.7 Million USD
    • The Company expects Q1 2024 Revenue to be in the range of $5.2 million to $5.3 million and is providing Q2 2024 Revenue Guidance of $5.7-$6.0 million
    • Fourth quarter 2023 gross margins improved to 51%, as compared to 27% in the fourth quarter of 2022
  • New “VINIA Inside” delivery systems set to launch, including Hot Beverage products, protein bars, hydration powders, and new Beauty/Anti Aging products
  • Major innovation pipeline planned in the polyphenol/antioxidant vertical with additional products being developed from Olive and Pomegranate cell banks
  • Strong IP platform with multiple patents obtained and pending
  • High Scalability with low cap ex requirements ($3-4M)
  • Significant leadership capability and Board/Advisory Board expertise
  • Current market capitalization offers significant upside
Vinia

Our news

The world leading plant-cell growth company

BioHarvest has transformed from a Research and Development company into a full-fledged end-to-end operation, with close to tripling revenues year over year on our Polyphenol Antioxidant Product business, new products and new market entries targeted for 2024, and the February 2024 launch of the CDMO Services business unit.

corporate presentation

Request a Meeting

Play Video
March 13, 2024

CDMO Launch & Corporate Update

CEO Ilan Sobel  and Chairman Zaki Rakib hosted an interactive discussion on the “Contract Development & Manufacturing” Business Unit”. This new division now establishes BioHarvest as a both a Products and a Services company –  developing plant based Direct-to-Consumer products from our proprietary cell banks, and developing new plant-based molecular compositions for industrial customers.

Play Video
March 14, 2024

BioHarvest Adds Key Hires to accelerate CDMO Business Unit

CEO Ilan Sobel is interviewed by Steve Darling of Proactive Investors to discuss growth opportunity of new Contract Development & Manufacturing division

Play Video
April 01 2023

Jerusalem Dateline -interviews senior BioHarvest executives

To explain the power of this unique biotechnology platform, as we grow plant cells without the plant.

0

Patents

0

Clinical Studies

0

Scientific Studies

0

Years R&D

$ 0

Million Invested

News Feed

Join the BioHarvest community via any of our shared content channels. Share our daily progress and our major news:

Facebook Youtube Email alternate_emailCreated with Sketch.

Our blog